 <h1>Tisagenlecleucel Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to tisagenlecleucel: intravenous suspension</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intravenous route (Suspension)</p><p>Warning: Cytokine release syndrome and neurological toxicitiesCytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving tisagenlecleucel. Do not administer tisagenlecleucel to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids.Neurological toxicities, which may be severe or life-threatening, can occur following treatment with tisagenlecleucel, including concurrently with CRS. Monitor for neurological events after treatment with tisagenlecleucel. Provide supportive care as needed.Tisagenlecleucel is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the KYMRIAH REMS.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, tisagenlecleucel may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking tisagenlecleucel:</p><p>
<i>More common</i>
</p><ul>
<li>Agitation</li>
<li>back pain</li>
<li>blue lips, fingernails, or skin</li>
<li>blurred vision</li>
<li>chest pain or discomfort</li>
<li>chills</li>
<li>confusion as to time, place, or person</li>
<li>cough</li>
<li>coughing that sometimes produces a pink frothy sputum</li>
<li>decreased urine output</li>
<li>depression</li>
<li>difficult, fast, noisy breathing</li>
<li>dilated neck veins</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>drowsiness</li>
<li>extreme fatigue</li>
<li>fast, pounding, or irregular heartbeat or pulse</li>
<li>fever</li>
<li>hallucinations</li>
<li>headache</li>
<li>hoarseness</li>
<li>holding false beliefs that cannot be changed by fact</li>
<li>hostility</li>
<li>increased sweating</li>
<li>irritability</li>
<li>loss of consciousness</li>
<li>lower back or side pain</li>
<li>mood or mental changes</li>
<li>muscle twitching</li>
<li>nausea</li>
<li>nervousness</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>pounding in the ears</li>
<li>rapid shallow breathing</li>
<li>rapid weight gain</li>
<li>seizures</li>
<li>slow or fast heartbeat</li>
<li>stiff neck</li>
<li>swelling of the face, arms, fingers, feet, or lower legs</li>
<li>trembling and shaking of hands</li>
<li>troubled breathing at rest</li>
<li>unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness</li>
<li>unusual excitement, nervousness, or restlessness</li>
<li>vomiting</li>
<li>weight gain</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Change in the amount of urine</li>
<li>cloudy urine</li>
<li>headache, sudden or severe</li>
<li>stomach pain</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of tisagenlecleucel may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Anxiety</li>
<li>decreased appetite</li>
<li>diarrhea</li>
<li>difficulty in moving</li>
<li>joint pain</li>
<li>muscle pain or stiffness</li>
<li>nasal congestion</li>
<li>pain in the arms or legs</li>
</ul><p>
<!-- end intravenous suspension --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to tisagenlecleucel: intravenous suspension</i></p><h3>General</h3><p>The most common adverse reactions (incidence greater than 30%) are cytokine release syndrome, hypogammaglobulinemia, infections-pathogen unspecified, prolonged neutropenia, pyrexia, decreased appetite, headache, encephalopathy, bleeding episodes, and hypotension.<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Cytokine release syndrome (79%), hypogammaglobulinemia (43%)</p>
<p><b>Common</b> (1% to 10%): Graft versus host disease<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Infections-pathogen unspecified (41%), pyrexia (40%), viral infectious disorders (26%), fatigue (22%), bacterial infectious disorders (19%), fungal infectious disorders (13%), face edema (10%), peripheral edema (10%), chills (10%)</p>
<p><b>Common</b> (1% to 10%): Multiple organ dysfunction syndrome<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Prolonged neutropenia (40%), prolonged thrombocytopenia (27%), hypofibrinogenemia with cytokine release syndrome (16%), increased international normalized ratio (13%)</p>
<p><b>Common</b> (1% to 10%): Disseminated intravascular coagulation, histiocytosis lymphocytic hemophagocytosis, coagulopathy</p>
<p><b>Frequency not reported</b>: Neutropenia, anemia, thrombocytopenia<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (37%), worsening hypokalemia (27%), worsening hypophosphatemia (19%), fluid overload (10%)</p>
<p><b>Common</b> (1% to 10%): Tumor lysis syndrome<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (37%), encephalopathy (34%)</p>
<p><b>Common</b> (1% to 10%): Tremor, intracranial hemorrhage, seizure</p>
<p><b>Frequency not reported</b>: Disturbances in consciousness, aphasia<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypotension (31%), bleeding episodes (31%), tachycardia (26%), hypertension (19%)</p>
<p><b>Common</b> (1% to 10%): Cardiac failure, cardiac arrest, capillary leak syndrome, prolonged activated partial thromboplastin time<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (26%), diarrhea (26%), vomiting (26%), constipation (18%), abdominal pain (16%)</p>
<p><b>Common</b> (1% to 10%): Abdominal compartment syndrome<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Hypoxia (24%), cough (19%), pulmonary edema (16%), tachypnea (12%), pleural effusion (10%), nasal congestion (10%)</p>
<p><b>Common</b> (1% to 10%): Respiratory distress, respiratory failure, acute respiratory distress syndrome<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Delirium (21%), anxiety (13%)</p>
<p><b>Frequency not reported</b>: Disorientation, confusion, agitation, mutism<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Pain in extremity (16%), myalgia (15%), arthralgia (12%), back pain (10%)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Increased blood creatinine<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased AST (28%), acute kidney injury (22%), increased ALT (21%), increased bilirubin (21%)<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Kymriah (tisagenlecleucel)." Novartis Pharmaceuticals, East Hanover, NJ. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What type of drug is Kymriah (tisagenlecleucel)?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about tisagenlecleucel</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: miscellaneous antineoplastics</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Tisagenlecleucel Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Kymriah</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Acute Lymphoblastic Leukemia</li>
<li>B Cell Lymphoma</li>
<li>Diffuse Large B-Cell Lymphoma</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to tisagenlecleucel: intravenous suspension</i></p><h3>General</h3><p>The most common adverse reactions (incidence greater than 30%) are cytokine release syndrome, hypogammaglobulinemia, infections-pathogen unspecified, prolonged neutropenia, pyrexia, decreased appetite, headache, encephalopathy, bleeding episodes, and hypotension.<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Cytokine release syndrome (79%), hypogammaglobulinemia (43%)</p><p><b>Common</b> (1% to 10%): Graft versus host disease<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Infections-pathogen unspecified (41%), pyrexia (40%), viral infectious disorders (26%), fatigue (22%), bacterial infectious disorders (19%), fungal infectious disorders (13%), face edema (10%), peripheral edema (10%), chills (10%)</p><p><b>Common</b> (1% to 10%): Multiple organ dysfunction syndrome<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Prolonged neutropenia (40%), prolonged thrombocytopenia (27%), hypofibrinogenemia with cytokine release syndrome (16%), increased international normalized ratio (13%)</p><p><b>Common</b> (1% to 10%): Disseminated intravascular coagulation, histiocytosis lymphocytic hemophagocytosis, coagulopathy</p><p><b>Frequency not reported</b>: Neutropenia, anemia, thrombocytopenia<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (37%), worsening hypokalemia (27%), worsening hypophosphatemia (19%), fluid overload (10%)</p><p><b>Common</b> (1% to 10%): Tumor lysis syndrome<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (37%), encephalopathy (34%)</p><p><b>Common</b> (1% to 10%): Tremor, intracranial hemorrhage, seizure</p><p><b>Frequency not reported</b>: Disturbances in consciousness, aphasia<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypotension (31%), bleeding episodes (31%), tachycardia (26%), hypertension (19%)</p><p><b>Common</b> (1% to 10%): Cardiac failure, cardiac arrest, capillary leak syndrome, prolonged activated partial thromboplastin time<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (26%), diarrhea (26%), vomiting (26%), constipation (18%), abdominal pain (16%)</p><p><b>Common</b> (1% to 10%): Abdominal compartment syndrome<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Hypoxia (24%), cough (19%), pulmonary edema (16%), tachypnea (12%), pleural effusion (10%), nasal congestion (10%)</p><p><b>Common</b> (1% to 10%): Respiratory distress, respiratory failure, acute respiratory distress syndrome<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Delirium (21%), anxiety (13%)</p><p><b>Frequency not reported</b>: Disorientation, confusion, agitation, mutism<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Pain in extremity (16%), myalgia (15%), arthralgia (12%), back pain (10%)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Increased blood creatinine<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased AST (28%), acute kidney injury (22%), increased ALT (21%), increased bilirubin (21%)<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Kymriah (tisagenlecleucel)." Novartis Pharmaceuticals, East Hanover, NJ. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What type of drug is Kymriah (tisagenlecleucel)?</li>
</ul><h2>More about tisagenlecleucel</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: miscellaneous antineoplastics</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Tisagenlecleucel Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Acute Lymphoblastic Leukemia</li>
<li>B Cell Lymphoma</li>
<li>Diffuse Large B-Cell Lymphoma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>